Claims for Patent: 8,617,598

Summary for Patent: 8,617,598

Title:	Pharmaceutical compositions comprising colloidal silicon dioxide
Abstract:	A pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight.
Inventor(s):	Haeberlin; Barbara (Munchenstein, CH), Kramer; Andrea (Reute, DE), Heuerding; Silvia (Basel, CH)
Assignee:	Novartis AG (Basel, CH)
Application Number:	13/489,396
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,617,598
Patent Claims:	1. A pharmaceutical composition in the form of a dispersible tablet to be dispersed in an ingestible liquid before administration to a patient, comprising a solid dispersion of 40-O-(2-hydroxy)ethyl-rapamycin, a disintegrant comprising cross-linked polyvinylpyrrolidone and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight and 10 to 30% of cross-linked polyvinylpyrrolidone by weight, and wherein the tablet has a disintegration time of 3 minutes or less and a hardness of 35 to 80N. 2. The pharmaceutical composition according to claim 1, wherein 250 mg of the composition, when compressed using a force of 8 to 11 kN with a 9 mm die and standard flat punches, forms the dispersible tablet. 3. A method of administering the pharmaceutical composition of claim 1 to a patient in need of said composition which comprises (i) contacting the composition with an aqueous solution (ii) allowing the composition to disperse in the aqueous solution to form a dispersed mixture and (iii) ingesting the dispersed mixture. 4. A composition according to claim 1, wherein the tablet has a disintegration time of 90 seconds or less. 5. A composition according to claim 1, wherein the composition is used as an immunosuppressant. 6. A process for producing the pharmaceutical composition according to claim 1, comprising preparing the solid dispersion comprising 40-O-(2-hydroxy)ethyl-rapamycin, mixing the solid dispersion comprising 40-O-(2-hydroxy)ethyl-rapamycin with the disintegrant comprising cross-linked polyvinylpyrrolidone and colloidal silicon dioxide to form the pharmaceutical composition and compressing the pharmaceutical composition to form the dispersible tablet.